Guerbet SA (GBT.PA)

38,50 +2,65 (+7,39 %) À partir de 02:37PM CEST. Marché ouvert.

Guerbet SA

15, rue des Vanesses
Zone Paris Nord II
Villepinte 93420
France
33 1 45 91 50 00
https://www.guerbet.com

Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 2 920

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. David Hale	CEO, MD & GM	998,04k	S.O.	1968
Mr. Jerome Estampes	CFO and Senior VP of Business Development & Licensing	S.O.	S.O.	S.O.
Ms. Sarah Dayre	Senior VP of Technical Operations & Interim Chief Pharmacist	S.O.	S.O.	S.O.
Ms. Charlotte Bamiere	Director of Legal Affairs	S.O.	S.O.	S.O.
Christine Allard	Senior Vice President of Public Affairs & Corporate Communications	S.O.	S.O.	S.O.
Eva Ohlsson	Senior Vice President of Human Resources	S.O.	S.O.	S.O.
Mr. Jean-Francois Blanc	Senior Vice President of Interventional Imaging	S.O.	S.O.	S.O.
Mr. Francois Nicolas	Senior VP of R&D, R&I and Chief Digital Officer	S.O.	S.O.	1971
Ms. Valérie Brissart	Senior Vice President of Diagnostic Imaging	S.O.	S.O.	S.O.
Mr. Mathieu Elie	Senior Vice President of Commercial Operations - Asia-Pacific	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Guerbet SA en date du 1 avril 2024 est 8. Les scores principaux sont Audit : 6; Société : 6; Droits des actionnaires : 7; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.